The Management of Malignant Ascites and Impact on Quality of Life Outcomes in Women with Ovarian Cancer

Overview

Journal Expert Rev Qual Life Cancer Care

Specialty Oncology

Date 2019 Mar 26

PMID 30906877

Citations 6

Authors

Larissa Meyer

Rudy Suidan

Charlotte Sun

Shannon Westin

Robert L Coleman

Gordon B Mills

Affiliations

Soon will be listed here.

Abstract

Malignant ascites is one of the most common sequela of epithelial ovarian cancer. It causes significant symptoms and can have a detrimental impact on patient quality of life, especially in women with recurrent ovarian cancer. The management of symptomatic ascites consists of both mechanical treatments that aim to drain the peritoneal cavity, and medical therapies that prevent and diminish the development of ascites. Mechanical options include serial paracentesis, peritoneal catheters, and peritoneovenous shunts. Pharmaceutical treatments include diuretics, angiogenesis inhibitors, and other targeted agents. There is a perception, without formal analysis, that intractable ascites is less common in the taxane era of therapy. In this review paper, we highlight current and emerging therapeutic strategies, complications and contraindications, and their effects on patient quality of life.

Citing Articles

Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.

Rickard B, Conrad C, Sorrin A, Ruhi M, Reader J, Huang S Cancers (Basel). 2021; 13(17).

PMID: 34503128 PMC: 8430600. DOI: 10.3390/cancers13174318.

A comparative analysis of different biofluids towards ovarian cancer diagnosis using Raman microspectroscopy.

Giamougiannis P, Morais C, Grabowska R, Ashton K, Wood N, Martin-Hirsch P Anal Bioanal Chem. 2020; 413(3):911-922.

PMID: 33242117 PMC: 7808972. DOI: 10.1007/s00216-020-03045-1.

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Alfaleh M, Alsaab H, Mahmoud A, Alkayyal A, Jones M, Mahler S Front Immunol. 2020; 11:1986.

PMID: 32983137 PMC: 7485114. DOI: 10.3389/fimmu.2020.01986.

Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer.

Asem M, Young A, Oyama C, ClaureDeLaZerda A, Liu Y, Ravosa M Sci Rep. 2020; 10(1):11913.

PMID: 32681052 PMC: 7367827. DOI: 10.1038/s41598-020-68639-2.

Management of drainage for malignant ascites in gynaecological cancer.

Kietpeerakool C, Rattanakanokchai S, Jampathong N, Srisomboon J, Lumbiganon P Cochrane Database Syst Rev. 2019; 12:CD007794.

PMID: 31825525 PMC: 6953277. DOI: 10.1002/14651858.CD007794.pub3.

References

Fleming N, Alvarez-Secord A, von Gruenigen V, Miller M, Abernethy A . Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage. 2009; 38(3):341-9. DOI: 10.1016/j.jpainsymman.2008.09.008. View

Keen A, Fitzgerald D, Bryant A, Dickinson H . Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev. 2010; (1):CD007794. PMC: 4170997. DOI: 10.1002/14651858.CD007794.pub2. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Rosenberg S, Courtney A, Nemcek Jr A, Omary R . Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol. 2004; 15(10):1129-31. DOI: 10.1097/01.RVI.0000136828.42612.B4. View

Aghajanian C, Goff B, Nycum L, Wang Y, Husain A, Blank S . Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015; 139(1):10-6. PMC: 4993045. DOI: 10.1016/j.ygyno.2015.08.004. View

Tarin D, Price J, Kettlewell M, Souter R, Vass A, Crossley B . Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 1984; 44(8):3584-92. View

Cella D, Neubauer N, Thomas J, Kutner J, Seiden M . The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecol Oncol. 2012; 128(2):187-90. DOI: 10.1016/j.ygyno.2012.11.013. View

Stockler M, Hilpert F, Friedlander M, King M, Wenzel L, Lee C . Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014; 32(13):1309-16. PMC: 4876313. DOI: 10.1200/JCO.2013.51.4240. View

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

10.

Iyengar T, Herzog T . Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care. 2002; 19(1):35-8. DOI: 10.1177/104990910201900108. View

11.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

12.

Tsikouras P, Tsagias N, Pinidis P, Csorba R, Vrachnis N, Dafopoulos A . The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Arch Gynecol Obstet. 2013; 288(3):581-5. DOI: 10.1007/s00404-013-2868-y. View

13.

Stewart M, Grippon S, Kirkpatrick P . Aflibercept. Nat Rev Drug Discov. 2012; 11(4):269-70. DOI: 10.1038/nrd3700. View

14.

Reynolds T . Renaissance of paracentesis in the treatment of ascites. Adv Intern Med. 1990; 35:365-73. View

15.

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M . Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013; 14(3):236-43. PMC: 3596061. DOI: 10.1016/S1470-2045(12)70567-3. View

16.

Hu L, Hofmann J, Holash J, Yancopoulos G, Sood A, Jaffe R . Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005; 11(19 Pt 1):6966-71. DOI: 10.1158/1078-0432.CCR-05-0910. View

17.

Brooks R, Herzog T . Long-term semi-permanent catheter use for the palliation of malignant ascites. Gynecol Oncol. 2006; 101(2):360-2. DOI: 10.1016/j.ygyno.2005.12.043. View

18.

Seike M, Maetani I, Sakai Y . Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol. 2007; 22(12):2161-6. DOI: 10.1111/j.1440-1746.2006.04793.x. View

19.

Sharma S, Walsh D . Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. J Pain Symptom Manage. 1995; 10(3):237-42. DOI: 10.1016/0885-3924(94)00129-9. View

20.

Zhao H, Li X, Chen D, Cai J, Fu Y, Kang H . Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Med Oncol. 2015; 32(2):292. DOI: 10.1007/s12032-014-0292-1. View